{
}
Prothena's stock surged nearly 40% after promising results from a midstage study of its Parkinson's treatment, prasinezumab, partnered with Roche. Although the drug missed its primary goal, it showed a delay in motor worsening, particularly in patients using levodopa, suggesting potential for future trials. Analysts estimate Prothena could earn up to $275 million in royalties, despite concerns about the drug's modest efficacy and administration challenges.
Roche's Parkinson's drug, prasinezumab, has failed a Phase IIb trial, despite showing potential clinical efficacy in delaying motor progression. While the results indicated positive trends in secondary endpoints, they lacked statistical significance, prompting analysts to call the data "promising but leaves uncertainty." Roche plans to continue related studies and may consider a new trial to further explore the findings.
Roche and Prothena's Parkinson's antibody treatment, prasinezumab, failed to meet its primary endpoint in the phase 2b PADOVA study, although it showed a 16% delay in motor progression compared to placebo. The drug was well tolerated, and Roche plans to further evaluate the data and collaborate with health authorities on next steps. Parkinson's disease remains difficult to treat, with many therapies struggling to progress through clinical trials.
Roche's phase 2b trial of prasinezumab, an anti-alpha-synuclein antibody partnered with Prothena, failed to meet its primary endpoint for treating early-stage Parkinson's disease, with a p value of 0.0657. However, Roche highlighted potential clinical efficacy in a subgroup receiving levodopa, showing a nominal p value of 0.0431. Despite the setbacks in alpha-synuclein targeting therapies, Roche plans to continue tracking patients and evaluate future steps after discussions with regulators.
UCB's investigational small molecule minzasolmin, developed in partnership with Novartis, has failed to meet primary and secondary endpoints in a phase 2a trial for early-stage Parkinson's disease, leading to the termination of its extension phase. The study, which involved 496 patients, showed comparable treatment-emergent adverse events across groups, with no new safety risks identified. UCB continues to explore alpha-synuclein pathology with other candidates, including UCB7583 and glovadalen, the latter of which is in a phase 2 trial with results expected in March 2025.
Prothena Corp PLC
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Prothena stock jumps nearly 40 percent on promising Parkinson's treatment results
18:28 19.12.2024
Roche's Parkinson's drug prasinezumab fails to achieve significant trial results
15:54 19.12.2024
roche and prothena's parkinsons antibody treatment fails in phase 2 trial
United States Dollar
UCB SA
Hoffmann-La Roche AG
Prothena Corp PLC
Novartis AG
BIOGEN
IRL
Levi Garraway
Show more
15:39 19.12.2024
Roche reports phase 2b failure for Parkinson's treatment but sees potential benefits
10:31 19.12.2024
ucb's parkinson's drug minzasolmin fails in phase 2 trial
United States Dollar
Prothena Corp PLC
Hoffmann-La Roche AG
UCB SA
BIOGEN
Novartis AG
CHE
BEL
USA
Show more
21:19 16.12.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Retail and Consumer Goods
Market Analysis and Predictions
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Energy Sector Developments
Startups & Entrepreneurship
Supply Chain Management
Financial Scams and Security
Government Policies
Central Bank Actions
Government Economic Policies
Domestic Politics
Workplace Trends
Countries:
Companies:
Tesla, Inc.
Barclays PLC
BNP Paribas SA
JPMorgan Chase & Co.
Apple Inc.
Raiffeisen Bank International AG
Deutsche Bank RV Global PP
Bank of America Corporation
UBS Group AG
NVIDIA Corporation
Morgan Stanley
Capital One Financial Corporation
The Goldman Sachs Group, Inc.
Citigroup Inc.
Berkshire Hathaway Inc.
Amazon.com, Inc.
SpaceXCoin USD
Commerzbank AG
Credit Suisse Real Estate Fund Siat
Wells Fargo & Company
Currencies:
United States Dollar
Euro
Chinese Yuan
Swiss Franc
Indian Rupee
British Pound Sterling
Vietnamese Đồng
Japanese Yen
Australian Dollar
Hong Kong Dollar
United Arab Emirates Dirham
Russian Ruble
Singapore Dollar
South Korean Won
Thai Baht
Norwegian Krone
Danish Krone
Swedish Krona
Ghanaian Cedi
Canadian Dollar
People: